Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia
Mani R, Mao Y, Frissora FW, et al.
Key Points:
Antitumor activity of OSU-2S, novel PP2A activator, explored in-vitro
OSU-2S-induced cytotoxicity associated with PKC dependent activation of tumor suppressor phosphatase SHP1, accompanied by downregulation of Tcl1A expression levels
Survival prolonged in Eµ-hROR1-Tcl1 spleen engrafted mouse models of CLL following treatment with OSU-2S immunoliposome (2A2-OSU-2S-ILP)
Implications:
- Further preclinical and clinical development warranted
View the original abstract on the ASH website.
